2. Anti-infection
  3. Bacterial
  4. Povidone iodine

Povidone iodine (iodopovidone) displays excellent antibacterial activity which can against MRSA and MSSA strains with MICs of 31.25 mg/L and 7.82 mg/L, respectively.

For research use only. We do not sell to patients.

Povidone iodine Chemical Structure

Povidone iodine Chemical Structure

CAS No. : 25655-41-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
5 g USD 25 In-stock
25 g USD 40 In-stock
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Povidone iodine Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Povidone iodine (iodopovidone) displays excellent antibacterial activity which can against MRSA and MSSA strains with MICs of 31.25 mg/L and 7.82 mg/L, respectively.

In Vitro

MIC values of Povidone iodine (iodopovidone) (PVP-I) are 31.25 mg/L and 7.82 mg/L, respectively. Treatment of the cells with Povidone iodine (PVP-I) at a dilution of 1:32 causes a sharp reduction in cell viability by 90-95% on all testing cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Povidone iodine Related Antibodies
In Vivo

The Dp+Povidone iodine (iodopovidone) (PVP-I) group has the second highest average score from day 13 to the end of the experimental period. The Dp+Povidone iodine and Dp+Et-OH groups also show a significantly increase in eosinophil count compare with the control group (p<0.05 and p<0.001, respectively). However, the eosinophil count does not significantly differ among the Dp+Povidone iodine (PVP-I), Dp+CHG, and Dp+vehicle groups[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
CAS No.
Appearance

Solid

Color

Pink to red

SMILES

II.O=C1N(C(C)CC)CCC1.[x].[n].[n:x].[=].[10:1]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 15 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 2.4 mg/mL (Need ultrasonic)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.5 mg/mL (Infinity mM); Clear solution

    This protocol yields a clear solution of ≥ 1.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1.5 mg/mL (Infinity mM); Clear solution

    This protocol yields a clear solution of ≥ 1.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (Infinity mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
Cell Assay
[1]

Each bacterial isolate is washed twice with phosphate-buffered saline (PBS, pH 7.2), centrifuged for 10 min at 1932xg at 20°C, and suspended in 3 mL of nutrient broth, adjusted to a turbidity equivalent of 0.5 McFarland standard. The bacterial suspension is diluted 1:100 with MHB to a final inoculum of 106 colony-forming units (cfu)/mL. For each bacterial strain, two rows of a 96-well microtitre plate are filled with the final bacterial inoculum (50 μL per well) and 50 μL of each serial dilution of ILαD. The procedure is repeated for the Povidone iodine (PVP-I) serial dilutions[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2]

The mice are divided into 6 groups as follows: 1) saline+vehicle (control group), 2) Dp+vehicle, 3) Dp+BZK, 4) Dp+Povidone iodine (PVP-I), 5) Dp+Et-OH, and 6) Dp+CHG. Animals in the experimental groups are exposed to the allergen through the subcutaneous injection of 5 µg of Dp dissolving in 10 µL of saline in the ventral side of the right ear 2 to 3 days a week (a total of 8 times) under anesthesia with 4% halothane. Animals in the control group are not sensitized, receiving a subcutaneous injection of 10 µL of saline in the ventral side of the right ear. Animals receive an application of antiseptic agent are exposed to the allergen and treated with 0.2% (w/v) benzalkonium chloride (Dp+BZK), 10% (w/v) povidone-iodine (Dp+PVP-I), 80% (v/v) ethanol (Dp+Et-OH) or 0.5% (v/v) chlorhexidine gluconate (Dp+CHG). These agents are applied a total of 15 times during the experimental period. The BZK, Povidone iodine (PVP-I), Et-OH, and CHG are dissolved in 25 µL of injection water and applied gently to the dorsal side of the right ear using a micropipette with a fine plastic tip. The animals in the Dp+vehicle and control groups receive 25 µL of injection water. All animals are sacrificed on the last day of the experiment (day 18)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Povidone iodine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Povidone iodine25655-41-8iodopovidoneBacterialInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Povidone iodine
Cat. No.:
HY-B2234
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.